The effect of clofazimine on liver function tests in lepra reaction (ENL).
Twenty patients with suspected DDS resistance and repeated attacks of lepra reactions were selected for the study. Clofazimine was administered in different doses over a period of 12 months. Elevated levels of transaminases and Alkaline phosphatase prior therapy attained values to near normalcy. Progressive fall in serum Bilirubin and Proteins with normal A/G ratio at the end of therapy was also observed. Clofazimine by its anti-inflammatory and antibacterial action could inhibit the process of liver damage and happened to have minimal deleterious effect on liver by studying the liver function tests.
D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D002991:Clofazimine / Q000494:pharmacology* / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D006801:Humans; D007918:Leprosy / Q000188:drug therapy*; D008099:Liver / Q000187:drug effects*; D008111:Liver Function Tests
D001798:Blood Proteins; D003622:Dapsone; D002991:Clofazimine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin